Healthcare Headlines

UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder. The company proposed an installment plan, with 315,000 euros paid up front and four additional annual payments due only if the treatment continues to be effective.

Top News Video

Top News